Anifrolumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interferon α/β receptor |
| Clinical data | |
| Routes of administration | Intravenous |
| ATC code | none |
| Identifiers | |
| CAS Number | 1326232-46-5 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6444H9964N1712O2018S44 |
| Molar mass | 145.12 kg/mol |
Anifrolumab[1] is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.[2]
This drug was developed by MedImmune. A Phase II clinical trial was completed in 2016. Two Phase III trials are planned as of August 2016.[3]
Adverse effects
The most common adverse effect in the study was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group. Overall adverse effect rates were comparable in all groups.[3]
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Anifrolumab, American Medical Association.
- 1 2 H. Spreitzer (29 August 2016). "Neue Wirkstoffe - Anifrolumab". Österreichische Apothekerzeitung (in German) (18/2016).
This article is issued from Wikipedia - version of the 9/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.